Laboratory Study of Early Tumor Markers in the Peripheral Blood of Glioblastoma Multiforme Patients

Human Glioblastoma Multiforme (GBM) Circulating Tumor Cells (CTCs) as Early, Less Invasive Markers of Progression and Response

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01135875

Enrollment

130

Registered

2010-06-03

Start date

2009-10-31

Completion date

2013-04-30

Last updated

2013-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioblastoma Multiforme, Healthy Volunteers

Keywords

GBM, Brain Tumor, Brain Neoplasm, Control, Normal Control, Volunteer

Brief summary

The purpose of this study is to determine if tumor cells can be detected in the blood of patients diagnosed with a brain tumor.

Detailed description

Despite aggressive therapies, Glioblastoma Multiforme (GBM) is rapidly fatal. GBMs are increasingly recognized for occasionally metastasizing through the peripheral blood to distant locations. This research study involves the detection and novel characterization of human GBM (hGBM) circulating tumor cells (CTCs) within the peripheral blood of brain tumor patients by identifying their unique cell surface antigen profile, determining an optimal isolation protocol, and quantitatively and qualitatively reporting the yield and characteristics.

Interventions

OTHERGBM Patients

2 teaspoons of blood will be collected during select clinic visits.

OTHERNormal Controls

2 teaspoons of blood will be collected once.

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 89 Years

Healthy volunteers

Yes

Inclusion criteria

* 18 to 89 years of age * Weight of at least 110 pounds * Able to provide informed consent for self

Exclusion criteria

* Patients with active malignant tumors other than GBM

Design outcomes

Primary

Measure	Time frame	Description
Identification of Human GBM CD Antigen Signature.	3 Years	Already established and stored GBM cell lines will be screened for CD antigens to confirm that a selective cell surface antigen can be identified.

Secondary

Measure	Time frame	Description
Identification & Isolation of Human GBM Cells in Seeded Normal Control Human Blood.	3 Years	Frozen and fresh human blood will be seeded with human GBM cells from established stored GBM cell lines and subjected to antibody-based cell identification and isolation procedures.
Prospective Isolation of GBM Tumor Cells in GBM Patient Blood.	3 Years	Circulating tumor cells will be isolated from blood drawn from GBM patients.
Prospective Evaluation of the Routine Medical History of GBM Patients.	3 Years	Medical records of GBM patients will be used to determine how circulating tumor cells impact outcome.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026